Search Orphan Drug Designations and Approvals
-
Generic Name: | 1-(fluoro-18F)-3-((2-((1E,3E)-4-(6-(methylamino)pyridin-3-yl)buta-1,3-dien-1-yl)benzo[d]thiazol-6-yl)oxy)propan-2-ol |
---|---|
Date Designated: | 11/01/2017 |
Orphan Designation: | A diagnostic for the management of progressive supranuclear palsy |
Orphan Designation Status: | Designated |
FDA Orphan Approval Status: | Not FDA Approved for Orphan Indication |
Sponsor: |
Aprinoia Therapeutics 17F, No. 3 Yuanqu Street Nangang District Taipei City 11503 Taiwan The sponsor address listed is the last reported by the sponsor to OOPD. |
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-